benefit-risk considerations during drug product development (8of14) redi 2018
Published 4 years ago • 4.9K plays • Length 40:26Download video MP4
Download video MP3
Similar videos
-
31:21
benefit-risk considerations in drug development (6/14) redi 2017
-
4:16
communicating benefit and risk information
-
41:06
division of risk management: overview of review activities and rems - pharmacovigilance 2020
-
41:00
fda regulatory requirements for clinical investigators and case examples (9of14) redi 2018
-
53:38
the active ind and available development programs (13of14) redi 2018
-
5:06
introducing the ibd benefit/risk assessment tool
-
43:14
introduction to regulatory science at the fda
-
37:46
clinical pharmacology regulatory sciences in drug development and precision medicine
-
46:00
introduction to investigational new drug (ind) applications (3/14) redi 2017
-
2:28
what is fda’s role in regulating drugs?
-
8:23
remarks by dr. hahn to the 2020 rx drug abuse and heroin summit
-
1:02:02
the development of drugs: benefit/risk assessment in chronic and rare diseases
-
32:21
good manufacturing practices (gmps) from an ind perspective (11of14) redi 2018
-
40:34
demystifying the investigational new drug (ind) application for drugs and biologics (3of14) redi '18
-
2:30
how regulatory science benefits patients
-
55:40
nonprescription drug product with an additional condition for nonprescription use
-
3:03
eu2p medicines benefit-risk assessment
-
3:17
how does the fda approve new drugs?
-
16:04
reducing risk in drug development through ai, physics, and cloud computing